Takeda's largest study brings dengue vaccine step closer

Published On 2017-04-08 04:49 GMT   |   Update On 2017-04-08 04:49 GMT

Japan's Takeda Pharmaceutical said it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business.


Japan's largest drug maker has taken a conscious decision to become more international under its French CEO Christophe Weber, who took over in 2015.


The international dengue study will test the experimental vaccine on 20,100 children and adolescents in eight countries in Latin America and Asia where the mosquito-borne disease is endemic. Initial results are expected in 2018.


Dengue kills about 20,000 people per year and infects hundreds of millions, and the virus is becoming much more prevalent and widespread.


Sanofi already has a dengue vaccine on the market, called Dengvaxia, but the French drug maker's product is not perfect and did not protect equally against the four different sero types of dengue in clinical tests.


As a result, academic researchers and rival manufacturers are continuing to work towards better vaccines. Takeda’s shot produced promising results against four dengue strains in earlier smaller studies.


Last November, Takeda announced it would invest more than 100 million euros ($107 million) to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News